Clinical Trials
23 trialsNCT05588609 2026-04-27
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
Partner Therapeutics, Inc.
Phase 2 Terminated
NCT02597946 2025-02-19
Afatinib in NSCLC With HER2 Mutation
Boehringer Ingelheim
Phase 2 Completed
NCT00748709 2025-02-11
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
Boehringer Ingelheim
Phase 2 Terminated
NCT03157089 2021-02-23
LUX-Lung-IO
Boehringer Ingelheim
Phase 2 Completed
NCT02780687 2020-11-18
LUX-Bladder 1
Boehringer Ingelheim
Phase 2 Completed
NCT01466660 2020-04-07
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
Boehringer Ingelheim
Phase 2 Completed
NCT01271725 2019-06-17
LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures
Boehringer Ingelheim
Phase 2 Completed
NCT00801294 2017-12-29
A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00727506 2017-08-15
BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma
Boehringer Ingelheim
Phase 2 Completed
NCT00525148 2016-09-16
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
Boehringer Ingelheim
Phase 2 Completed
NCT00514943 2016-07-26
BIBW 2992 (Afatinib) in Head & Neck Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT01441596 2015-09-07
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases
Boehringer Ingelheim
Phase 2 Completed
NCT00706628 2015-01-15
A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00711594 2015-01-15
LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
Boehringer Ingelheim
Phase 2 Completed
NCT00796549 2014-07-22
BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients
Boehringer Ingelheim
Phase 2 Completed
NCT01152437 2014-06-26
A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00431067 2014-06-09
Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
Boehringer Ingelheim
Phase 2 Completed
NCT00730925 2014-03-26
Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients
Boehringer Ingelheim
Phase 2 Completed
NCT00425854 2013-12-31
An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00826267 2013-12-31
6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab
Boehringer Ingelheim
Phase 2 Completed
NCT01003899 2013-12-31
A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]
Boehringer Ingelheim
Phase 2 Completed
NCT00708214 2013-12-30
BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00875433 2013-12-30
Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours
Boehringer Ingelheim
Phase 2 Completed